GenmabGMAB
GMAB
About: Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Employees: 2,638
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
63% more call options, than puts
Call options by funds: $15.4M | Put options by funds: $9.44M
38% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 66
6.19% more ownership
Funds ownership: 91.83% [Q4 2024] → 98.02% (+6.19%) [Q1 2025]
1% more capital invested
Capital invested by funds: $1.27B [Q4 2024] → $1.28B (+$10.5M) [Q1 2025]
8% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 40
4% less funds holding
Funds holding: 227 [Q4 2024] → 218 (-9) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$37
62%
upside
Avg. target
$37
62%
upside
High target
$37
62%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 62%upside $37 | Buy Reiterated | 9 Apr 2025 |
Financial journalist opinion
Based on 13 articles about GMAB published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Neutral
GlobeNewsWire
4 days ago
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 10, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Neutral
The Motley Fool
1 week ago
Why Genmab Stock Smashed It on Monday
On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (GMAB 3.94%), on the back of encouraging news from the laboratory.
Neutral
Business Wire
1 week ago
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months, treatment with Rina-S 100 mg/m2 every 3 weeks (Q3W) resulted in a 50.0 percent confirmed objective response rate (ORR), including two complete.
Neutral
GlobeNewsWire
1 week ago
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Neutral
GlobeNewsWire
2 weeks ago
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
Media Release COPENHAGEN, Denmark; May 27, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the 4 6 th Goldman Sachs Annual Global Health c are Conference in Miami, Florida at 8:00 A M E D T ( 2:00 PM CE S T ) on June 9 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Neutral
GlobeNewsWire
2 weeks ago
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Neutral
GlobeNewsWire
3 weeks ago
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release COPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S ® ) in patients with recurrent/advanced endometrial cancer Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Genmab A/S (Nasdaq: GMAB ) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRa)-targeted, TOPO1-inhibor antibody-drug conjugate (ADC), in patients with recurrent/advanced endometrial cancer.
Neutral
Business Wire
3 weeks ago
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRa)-.
Neutral
GlobeNewsWire
3 weeks ago
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
Media Release COPENHAGEN, Denmark; May 21, 2025 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference in New York City, New York at 9:20 EDT ( 3 : 2 0 PM CE S T) on June 5 , 2025. A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Charts implemented using Lightweight Charts™